featured
Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes: A Meta-Analysis of Individual Patient Data
Lancet Diabetes Endocrinol 2016 Feb 08;[EPub Ahead of Print], N Sattar, D Preiss, JG Robinson, CS Djedjos, M Elliott, R Somaratne, SM Wasserman, FJ RaalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.